Article 4 Grand Pharma attaches great importance to information security and strives to ensure the confidentiality, integrity and availability of the Company's information assets. The Company undertakes to implement the following principles and measures in all business activities:

(i) Continuous Improvement of Information Security Management System.

[redacted]

Article 6 The Company may use personal information for the following purposes:

(i) Receiving opinions or inquiries submitted by data subjects and providing corresponding service support;



[illegible]

- [illegible]
- Personal informa[illegible]
- Our pr[illegible] data s[illegible]ect;
- The [illegible]pos[illegible] nece[illegible]
- The [illegible] inform[illegible]

(iv) Right[illegible] purp[illegible] pro[illegible] ex[illegible] is[illegible]

(v) [illegible]

(vi) [illegible]

(vii) [illegible]



responsible for related outcomes and decisions, and have governance structures and response processes in place to properly handle any unexpected consequences or harm.

(vii) Defining clear boundaries. Clearly define the boundaries for what AI can and cannot do, standardize its applicable scenarios and ways of use, preventing overstepping or improper use.

(viii) Low ecological footprint. Requiring (own/third-party) AI data centers/models to have a low ecological footprint, considering energy efficiency and sustainability in tech selection and deployment.

(ix) Not using illegal AI systems. The Company does not use or deploy AI systems that involve manipulative behavior, exploitation of vulnerabilities, social scoring or unauthorized biometric surveillance, When using AI systems, the Company shall comply with the provisions of Chinese laws and regulations, including the Interim Measures for the Management of Generative Artificial Intelligence Services, as well as other

